指南与共识肝肾功能剂量调整

从Cockcroft-Gault肌酐清除率转向无种族eGFR以改善用药决策:NKF共识

Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions.
指南 / 共识 · Am J Health Syst Pharm · 2025-01-01

美国国家肾脏基金会工作组发布共识,建议在成人稳定肾功能下,用无种族估计肾小球滤过率(eGFR)替代Cockcroft-Gault估计肌酐清除率(C-G eCrCL)进行医疗和用药决策,并在eGFR基础上按体表面积(BSA)调整以优化用药决策。

要点

  • 2024年FDA指南推荐用eGFR而非C-G eCrCL评估肾功能损害对药代动力学的影响。
  • NKF与ASN联合工作组推荐3个无种族CKD-EPI eGFR方程用于医疗和用药决策。
  • 当BSA高于或低于1.73 m2时,应对eGFR结果进行BSA调整以改善用药决策。

核心结论

  • NKF工作组建议卫生系统、临床实验室、电子健康记录系统、药品数据库及从业人员从C-G eCrCL转向无种族eGFR方程,以更准确评估肾脏滤过并保持用药决策一致性。

研究设计与样本

  • 美国国家肾脏基金会(NKF)无种族eGFR用药决策实施工作组发布的共识文件。

主要发现

  • 美国药师主要使用C-G eCrCL进行用药决策,尽管存在更准确的eGFR方程。
  • 推动转变的因素包括2024年FDA指南、NKF与ASN联合工作组推荐、标准化血清肌酐检测的普及以及血清胱抑素C的可用性增加。

关键数值与推荐

  • 推荐使用3个无种族CKD-EPI eGFR方程进行医疗和用药决策。
  • 当个体BSA高于或低于1.73 m2时,应对eGFR结果进行BSA调整以改善用药决策。

临床怎么用

  • 在成人稳定肾功能下,用药决策应使用无种族eGFR方程替代C-G eCrCL。
  • 当BSA不等于1.73 m2时,需对eGFR进行BSA调整后再用于用药决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The goals of this paper are to (1) provide evidence and expert consensus to support a unified approach to estimating kidney filtration in adults with stable kidney function using race-free estimated glomerular filtration rate (eGFR) in place of Cockcroft-Gault estimated creatinine clearance (C-G eCrCL) for medical and medication-related decisions, and (2) demonstrate how adjusting eGFR results for an individual's body surface area (BSA) when it is higher or lower than 1.73 m2 will improve results for medication-related decisions. SUMMARY: C-G eCrCL is predominantly used by US pharmacists to determine eGFR for the purposes of medication-related decisions, even though more accurate eGFR equations exist. Several driving factors make it the ideal time to shift clinical practice from using C-G eCrCL to eGFR. These factors include the following: (1) 2024 Food and Drug Administration (FDA) guidance for industry recommends eGFR over C-G eCrCL to evaluate the impact on pharmacokinetics in patients with impaired kidney function; (2) a joint National Kidney Foundation (NKF) and American Society of Nephrology task force recommends 3 race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR equations for medical and medication-related decision-making; (3) the almost ubiquitous use of standardized serum creatinine assay methods in US clinical laboratories; and (4) increasing availability and use of serum cystatin C for eGFR assessment. This publication guides practitioners through the rationale for using race-free eGFR equations for medication-related decisions and how to implement this practice change. CONCLUSION: The NKF Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions suggests that health systems, health settings, clinical laboratories, electronic health record systems, compendia and data vendors, and healthcare practitioners involved with medication-related decision-making transition away from C-G eCrCL and towards the race-free eGFR equations for more accurate assessment of kidney filtration and consistency in medication and medical decision-making across the US.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. St Peter WL, Bzowyckyj AS, Anderson-Haag T, et al. Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions. Am J Health Syst Pharm. 2025. PMID: 39552516. doi:10.1093/ajhp/zxae317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。